Phathom Pharmaceuticals (PHAT) Income from Continuing Operations (2022 - 2025)
Historic Income from Continuing Operations for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$30.0 million.
- Phathom Pharmaceuticals' Income from Continuing Operations rose 6498.03% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 1914.08%. This contributed to the annual value of -$334.3 million for FY2024, which is 6599.37% down from last year.
- Phathom Pharmaceuticals' Income from Continuing Operations amounted to -$30.0 million in Q3 2025, which was up 6498.03% from -$75.7 million recorded in Q2 2025.
- Phathom Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$30.0 million for Q3 2025, and its period low was -$94.3 million during Q1 2025.
- Its 4-year average for Income from Continuing Operations is -$62.2 million, with a median of -$55.0 million in 2022.
- Per our database at Business Quant, Phathom Pharmaceuticals' Income from Continuing Operations crashed by 12319.86% in 2024 and then surged by 6498.03% in 2025.
- Quarter analysis of 4 years shows Phathom Pharmaceuticals' Income from Continuing Operations stood at -$55.0 million in 2022, then tumbled by 44.76% to -$79.6 million in 2023, then grew by 6.36% to -$74.5 million in 2024, then surged by 59.78% to -$30.0 million in 2025.
- Its last three reported values are -$30.0 million in Q3 2025, -$75.7 million for Q2 2025, and -$94.3 million during Q1 2025.